267 related articles for article (PubMed ID: 32096344)
1. Local delivery of dinutuximab from lyophilized silk fibroin foams for treatment of an orthotopic neuroblastoma model.
Ornell KJ; Taylor JS; Zeki J; Ikegaki N; Shimada H; Coburn JM; Chiu B
Cancer Med; 2020 Apr; 9(8):2891-2903. PubMed ID: 32096344
[TBL] [Abstract][Full Text] [Related]
2. Development of a dinutuximab delivery system using silk foams for GD2 targeted neuroblastoma cell death.
Ornell KJ; Chiu B; Coburn JM
J Biomed Mater Res A; 2021 Aug; 109(8):1393-1405. PubMed ID: 33252182
[TBL] [Abstract][Full Text] [Related]
3. Enhancing sustained-release local therapy: Single versus dual chemotherapy for the treatment of neuroblastoma.
Taylor JS; Yavuz B; Zeki J; Wood L; Ikegaki N; Coburn J; Harrington K; Shimada H; Kaplan DL; Chiu B
Surgery; 2020 Jun; 167(6):969-977. PubMed ID: 32122657
[TBL] [Abstract][Full Text] [Related]
4. Silk Reservoirs for Local Delivery of Cisplatin for Neuroblastoma Treatment: In Vitro and In Vivo Evaluations.
Yavuz B; Zeki J; Taylor J; Harrington K; Coburn JM; Ikegaki N; Kaplan DL; Chiu B
J Pharm Sci; 2019 Aug; 108(8):2748-2755. PubMed ID: 30905702
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells.
Wu HW; Sheard MA; Malvar J; Fernandez GE; DeClerck YA; Blavier L; Shimada H; Theuer CP; Sposto R; Seeger RC
Clin Cancer Res; 2019 Aug; 25(15):4761-4774. PubMed ID: 31068371
[TBL] [Abstract][Full Text] [Related]
6. Disseminated injection of vincristine-loaded silk gel improves the suppression of neuroblastoma tumor growth.
Zeki J; Taylor JS; Yavuz B; Coburn J; Ikegaki N; Kaplan DL; Chiu B
Surgery; 2018 Oct; 164(4):909-915. PubMed ID: 30061039
[TBL] [Abstract][Full Text] [Related]
7. Implantable chemotherapy-loaded silk protein materials for neuroblastoma treatment.
Coburn J; Harris J; Zakharov AD; Poirier J; Ikegaki N; Kajdacsy-Balla A; Pilichowska M; Lyubimov AV; Shimada H; Kaplan DL; Chiu B
Int J Cancer; 2017 Feb; 140(3):726-735. PubMed ID: 27770551
[TBL] [Abstract][Full Text] [Related]
8. Small extracellular vesicles induce resistance to anti-GD2 immunotherapy unveiling tipifarnib as an adjunct to neuroblastoma immunotherapy.
Liu X; Wills CA; Chen L; Zhang J; Zhao Y; Zhou M; Sundstrom JM; Schell T; Spiegelman VS; Young MM; Wang HG
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35483745
[TBL] [Abstract][Full Text] [Related]
9. TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells.
Tran HC; Wan Z; Sheard MA; Sun J; Jackson JR; Malvar J; Xu Y; Wang L; Sposto R; Kim ES; Asgharzadeh S; Seeger RC
Clin Cancer Res; 2017 Feb; 23(3):804-813. PubMed ID: 27756784
[TBL] [Abstract][Full Text] [Related]
10. Initiation of immunotherapy with activated natural killer cells and anti-GD2 antibody dinutuximab prior to resection of primary neuroblastoma prolongs survival in mice.
Zobel MJ; Zamora AK; Wu HW; Sun J; Lascano D; Malvar J; Wang L; Sheard MA; Seeger RC; Kim ES
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428582
[TBL] [Abstract][Full Text] [Related]
11. G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment.
Martinez Sanz P; van Rees DJ; van Zogchel LMJ; Klein B; Bouti P; Olsman H; Schornagel K; Kok I; Sunak A; Leeuwenburg K; Timmerman I; Dierselhuis MP; Kholosy WM; Molenaar JJ; van Bruggen R; van den Berg TK; Kuijpers TW; Matlung HL; Tytgat GAM; Franke K
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049929
[TBL] [Abstract][Full Text] [Related]
12. GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma.
Zirngibl F; Ivasko SM; Grunewald L; Klaus A; Schwiebert S; Ruf P; Lindhofer H; Astrahantseff K; Andersch L; Schulte JH; Lode HN; Eggert A; Anders K; Hundsdoerfer P; Künkele A
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34285106
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of MYCN protein by CX-5461 leads to neuroblastoma tumor growth suppression.
Taylor JS; Zeki J; Ornell K; Coburn J; Shimada H; Ikegaki N; Chiu B
J Pediatr Surg; 2019 Jun; 54(6):1192-1197. PubMed ID: 30879743
[TBL] [Abstract][Full Text] [Related]
14. Activated Natural Killer Cells in Combination with Anti-GD2 Antibody Dinutuximab Improve Survival of Mice after Surgical Resection of Primary Neuroblastoma.
Barry WE; Jackson JR; Asuelime GE; Wu HW; Sun J; Wan Z; Malvar J; Sheard MA; Wang L; Seeger RC; Kim ES
Clin Cancer Res; 2019 Jan; 25(1):325-333. PubMed ID: 30232225
[TBL] [Abstract][Full Text] [Related]
15. Dinutuximab for the treatment of pediatric patients with neuroblastoma.
Greenwood K; Foster JH
Drugs Today (Barc); 2017 Sep; 53(9):469-476. PubMed ID: 29238760
[TBL] [Abstract][Full Text] [Related]
16. Manipulation of variables in local controlled release vincristine treatment in neuroblastoma.
Coburn JM; Harris J; Cunningham R; Zeki J; Kaplan DL; Chiu B
J Pediatr Surg; 2017 Dec; 52(12):2061-2065. PubMed ID: 28927981
[TBL] [Abstract][Full Text] [Related]
17. The safety of dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.
Greenwood KL; Foster JH
Expert Opin Drug Saf; 2018 Dec; 17(12):1257-1262. PubMed ID: 30433831
[TBL] [Abstract][Full Text] [Related]
18. Lyophilized silk fibroin hydrogels for the sustained local delivery of therapeutic monoclonal antibodies.
Guziewicz N; Best A; Perez-Ramirez B; Kaplan DL
Biomaterials; 2011 Apr; 32(10):2642-50. PubMed ID: 21216004
[TBL] [Abstract][Full Text] [Related]
19. IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models.
Stip MC; Evers M; Nederend M; Chan C; Reiding KR; Damen MJ; Heck AJR; Koustoulidou S; Ramakers R; Krijger GC; de Roos R; Souteyrand E; Cornel AM; Dierselhuis MP; Jansen M; de Boer M; Valerius T; van Tetering G; Leusen JHW; Meyer-Wentrup F
J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37479484
[TBL] [Abstract][Full Text] [Related]
20. Dinutuximab: first global approval.
Dhillon S
Drugs; 2015 May; 75(8):923-7. PubMed ID: 25940913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
